Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma

A study investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy).